What is the appropriate diagnostic workup and management for anemia of chronic disease?

Anemia of Chronic Disease: Diagnostic Workup and Management

Anemia of chronic disease (ACD) requires a systematic diagnostic approach centered on ferritin and transferrin saturation interpretation in the context of inflammation, followed by treatment of the underlying condition and consideration of intravenous iron when functional iron deficiency is present.

Diagnostic Workup

Initial Laboratory Assessment

In the presence of inflammation (elevated CRP), ferritin >100 μg/L combined with transferrin saturation <20% confirms pure anemia of chronic disease. 1, 2 This pattern reflects hepcidin-mediated iron sequestration in macrophages, creating functional iron deficiency where iron is trapped and unavailable for erythropoiesis. 1

• Ferritin 30-100 μg/L indicates mixed iron deficiency and ACD, requiring treatment for both conditions. 1, 3
• Ferritin <30 μg/L signifies true iron deficiency rather than pure ACD. 3
• Transferrin saturation <20% reliably identifies functional iron deficiency even when ferritin appears adequate. 2

Critical pitfall: Ferritin alone is unreliable when CRP is elevated—values >100 μg/L do not exclude functional iron deficiency because ferritin rises as an acute-phase reactant during inflammation. 2

Complete Blood Count Characteristics

• Mild to moderate normocytic anemia (hemoglobin typically 9-11 g/dL) with reduced MCHC and elevated RDW is characteristic. 2, 4
• Inappropriately normal or low reticulocyte percentage for the degree of anemia indicates inadequate bone marrow response typical of ACD. 2
• Low transferrin concentration in the setting of high CRP confirms ACD, reflecting inflammation-induced suppression of transferrin synthesis. 2

Investigation of Underlying Inflammatory Conditions

All patients with ACD and elevated inflammatory markers require investigation for the underlying cause:

• Bidirectional endoscopy (upper endoscopy with duodenal biopsies plus colonoscopy) to exclude gastrointestinal malignancy, celiac disease, peptic ulcer disease, inflammatory bowel disease, and angiodysplasia—particularly in patients over 75 years. 2
• Serum creatinine and estimated GFR to assess for chronic kidney disease, which contributes to normocytic anemia via reduced erythropoietin production and functional iron deficiency. 1, 2
• BNP measurement and clinical assessment for chronic heart failure, which causes anemia through inflammation, hemodilution, and impaired iron mobilization. 1, 2
• Focused history for inflammatory bowel disease, rheumatologic disorders (especially rheumatoid arthritis), and chronic infections. 2, 3
• Vitamin B12 and folate levels to exclude megaloblastic anemia as a contributing factor. 2, 3

Failure to investigate for gastrointestinal malignancy can miss the primary source of chronic inflammation driving the anemia. 2

Management Algorithm

First-Line: Treat the Underlying Inflammatory Condition

The cornerstone of ACD management is intensifying therapy for the underlying inflammatory disease, as this directly addresses the pathophysiology by reducing hepcidin production and restoring iron mobilization. 3 Controlling inflammation with disease-modifying therapy (e.g., anti-TNF agents in rheumatoid arthritis) can significantly improve hemoglobin levels. 3

Second-Line: Iron Supplementation

Oral iron therapy is generally ineffective in ACD with elevated hepcidin because hepcidin blocks duodenal iron absorption and iron release from macrophages. 2, 3

Intravenous iron should be used when:

• The underlying inflammatory condition cannot be rapidly corrected. 2
• Transferrin saturation is ≤20% and ferritin is ≤500 μg/L. 3
• The patient has clinically active disease with hemoglobin <10 g/dL. 3
• Previous intolerance to oral iron has occurred. 3

IV iron bypasses hepcidin-mediated blockade and can raise hemoglobin by ≥2 g/dL within 4 weeks. 1, 2 A trial of weekly IV iron (50-125 mg) for 8-10 doses can differentiate functional iron deficiency from pure inflammatory inhibition; a hemoglobin rise indicates functional deficiency, whereas lack of response suggests dominant inflammation. 2

Monitor ferritin during IV iron therapy and keep ≤500 μg/L to avoid iron overload without added therapeutic benefit. 2

Third-Line: Erythropoiesis-Stimulating Agents (ESAs)

ESAs should be used with caution and only when:

• Hemoglobin is consistently below 10 g/dL. 3
• The patient has significant symptoms attributable to anemia. 3
• There is insufficient response to iron therapy and optimized treatment of underlying disease. 3
• Target hemoglobin should not exceed 12 g/dL. 3

Avoid ESAs in patients with:

• Active malignancy (potential for tumor progression). 3
• Heart failure or coronary heart disease with mild to moderate anemia (cardiovascular risks). 3

Blood Transfusions

Reserve blood transfusions for:

• Hemoglobin <7 g/dL. 3
• Symptomatic anemia not responding to other therapies. 3
• Acute decompensation or hemodynamic instability. 3

Use a restrictive transfusion strategy (trigger threshold 7-8 g/dL) in patients with heart disease. 3

Special Population Considerations

Chronic Kidney Disease (CKD)

• Absolute iron deficiency in CKD is defined as transferrin saturation ≤20% with ferritin ≤100 μg/L (predialysis/peritoneal dialysis) or ≤200 μg/L (hemodialysis). 1
• Oral iron may be tried in predialysis patients, but IV iron is required if not tolerated, ineffective, or if dialysis has commenced. 1
• **ESAs may be used when hemoglobin <10 g/dL after confirming iron repletion** (transferrin saturation >20%). 2
• Management should be coordinated with nephrology. 1

Chronic Heart Failure (CHF)

• Iron deficiency is defined as ferritin <100 μg/L and/or transferrin saturation <20% in CHF patients. 1
• Intravenous iron has shown prognostic benefit even without overt anemia and should be considered for both absolute and functional iron deficiency. 1
• No prognostic benefit has been demonstrated for oral iron, which is poorly absorbed due to gut edema. 1

Inflammatory Bowel Disease (IBD)

• Iron supplementation is recommended in all IBD patients with iron deficiency anemia. 1
• Ferritin levels up to 100 μg/L may still reflect iron deficiency in the presence of inflammation. 1
• IV iron is preferred as first-line treatment in patients with active disease regardless of hemoglobin level if ferritin and transferrin saturation criteria are met. 3

Monitoring Protocol

• Measure hemoglobin at least every 3 months in patients with chronic disease and anemia. 3
• Monitor iron parameters (ferritin, transferrin saturation) every 3 months during therapy. 3
• Assess symptoms of anemia (fatigue, exercise tolerance, quality of life) at each visit. 3
• Re-treat with IV iron when ferritin drops below 100 μg/L or hemoglobin falls below 12 g/dL (women) or 13 g/dL (men). 3

Common Pitfalls to Avoid

• Not all normocytic anemia is ACD—early iron deficiency, myelodysplastic syndromes, and mixed deficiencies can present with normal MCV, and an elevated RDW signals evolving microcytosis or mixed pathology. 2
• Empiric oral iron supplementation without first identifying the cause is discouraged in patients with elevated inflammatory markers; priority should be given to diagnosing and treating the underlying condition. 2
• Ferritin values >100 μg/L do not exclude functional iron deficiency and should be interpreted alongside transferrin saturation or an IV iron trial. 2